Cost-minimization Analysis of 3 Therapeutic Regimes of Edaravone Combined Use in the Treatment of Acute Cerebral Infarction / 中国药房
China Pharmacy
;
(12): 581-583, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-504291
ABSTRACT
OBJECTIVE:
To explore the pharmacoeconomic effect of Ginkgo dipyidamolum,argatroban or sodium ozagerl combined with edaravone in the treatment of acute cerebral infarction(ACI).METHODS:
In retrospective study,64 ACI patients were divided into group A(Ginkgo dipyidamolum+edaravone,22 cases),group B(argatroban+edaravone,19 cases)and group C (sodium ozagerl+edaravone,23 cases). Therapeutic efficacies were observed after 7-14 days of treatment;therapy cost was calculat-ed,and cost-minimization analysis was used to evaluate pharmacoeconomics.RESULTS:
There was no statistical significance in to-tal effective rate among 3 groups(P>0.05);the costs of group A,group B and group C were 8 746.36 yuan,10 770.64 yuan and 8 264.67 yuan. Results of sensitivity analysis were in line with those of cost-minimization analysis.CONCLUSIONS:
Therapy plan of sodium ozagerl+edaravone is the economical regime in the treatment of ACI .
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Health economic evaluation
/
Observational study
Language:
Chinese
Journal:
China Pharmacy
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS